Non-Melanoma Skin Cancers CPG Mini Module – Overcoming Immune Evasion in Merkel Cell Carcinoma
The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.
In this mini module, Shailender Bhatia, MD, of Fred Hutchinson Cancer Center, presents a case study of a patient with multi-focal virus-negative Merkel cell carcinoma that recurred after several lines of therapy. This presentation addresses the importance of persisting and trying multiple lines of immunotherapy to generate an immune response. This presentation also touches on considerations such as disease control prior to immunotherapy, access to clinical trials, and the time needed to develop an anti-cancer immune response.
Run Time: 13 Minutes 10 Seconds
Target Audience
Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021).
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.